» Articles » PMID: 20061010

Mast Cells from Different Molecular and Prognostic Subtypes of Systemic Mastocytosis Display Distinct Immunophenotypes

Overview
Date 2010 Jan 12
PMID 20061010
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Systemic mastocytosis (SM) is a heterogeneous group of disorders with distinct clinical and biological behavior. Despite this, little is known about the immunophenotypic features of the distinct diagnostic categories of SM.

Objective: To analyze the immunophenotypic characteristics of bone marrow (BM) mast cells (MCs) of different subtypes of SM.

Methods: Bone marrow samples from 123 patients with different subtypes of SM and 92 controls were analyzed for a broad panel of immunophenotypic markers by flow cytometry.

Results: Three clearly different maturation-associated immunophenotypic profiles were found for BMMCs in SM. These different profiles were associated with both genetic markers of the disease and its clinical behavior. BMMCs from poor-prognosis categories of SM (aggressive SM and MC leukemia) typically showed an immature phenotype with clonal involvement of all myeloid lineages by the D816V stem cell growth factor receptor gene (KIT) mutation. In turn, a mature activated versus resting BMMC immunophenotype was commonly found among patients with good-prognosis subtypes of SM depending on whether they carried (indolent SM and clonal MC activation disorders) or not (well differentiated SM) the D816V KIT mutation.

Conclusion: Bone marrow MCs from SM show 3 different maturation-related immunophenotypic profiles that are associated with both the genetic markers of the disease and its clinical behavior.

Citing Articles

Detection of Mutations in Systemic Mastocytosis: How, When, and Why.

Cilloni D, Maffeo B, Savi A, Danzero A, Bonuomo V, Fava C Int J Mol Sci. 2024; 25(20).

PMID: 39456668 PMC: 11507058. DOI: 10.3390/ijms252010885.


Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.

Zaremba-Pataj E, Patkowska E, Krzywdzinska A, Szumera-Cieckiewicz A, Chlebowska-Tuz J J Hematop. 2024; 16(1):39-47.

PMID: 38175371 DOI: 10.1007/s12308-022-00526-3.


Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation.

Parente R, Giudice V, Cardamone C, Serio B, Selleri C, Triggiani M Int J Mol Sci. 2023; 24(8).

PMID: 37108232 PMC: 10139107. DOI: 10.3390/ijms24087071.


Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors.

Manachai N, Rattanapinyopituk K, Fonghem P, Phoomvuthisarn P, Nakahata S, Morishita K Vet Med Int. 2022; 2022:9509900.

PMID: 36072760 PMC: 9441376. DOI: 10.1155/2022/9509900.


Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features.

Rama T, Morgado J, Henriques A, Escribano L, Alvarez-Twose I, Sanchez-Munoz L Clin Transl Allergy. 2022; 12(3):e12132.

PMID: 35344302 PMC: 8967266. DOI: 10.1002/clt2.12132.